Business Context and Reporting Period
This Form 8-K filing by Moderna, Inc. (Delaware) reports on events occurring on December 11, 2018, coinciding with the consummation of the Company's initial public offering (IPO). The filing details corporate governance amendments effective upon the IPO closing.
Financial Metrics
This filing does not contain financial performance data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The filing reports the following material changes to the Company's corporate structure:
- Amended and Restated Certificate of Incorporation:
- Authorized 1,600,000,000 shares of common stock.
- Eliminated all references to previously existing series of preferred stock.
- Authorized 162,000,000 shares of undesignated preferred stock for future issuance by the Board.
- Amended and Restated By-laws:
- Eliminated the ability of stockholders to take action by written consent or call special meetings.
- Established procedures for stockholder proposals and director nominations.
- Conformed by-laws to the new Certificate of Incorporation.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly a notice of corporate charter amendments.
Key Facts for Investor Verification
- Verify the total authorized share count (1.6 billion common; 162 million undesignated preferred).
- Confirm the elimination of written consent rights for stockholders under the new By-laws.
- Review the attached exhibits (3.1 and 3.2) for the full legal text of the Restated Certificate and By-laws.
- Note that this filing does not provide financial results; refer to the Form S-1 Registration Statement for IPO financial data.
